Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. Special ...

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial ...

Inovio Pharmaceuticals Inc (NASDAQ:INO) has resolved the manufacturing issue with the single-use array component of the Selectra device, which is crucial for their BLA submission for INO 3,107. The ...

The company reiterated its plan to submit the BLA for INO-3107 under the FDA's rolling submission process in mid-2025, aiming for FDA acceptance of the filing by year-end and a potential PDUFA date in ...

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported second quarter 2025 financial results and outlined key milestones in its effort to bring INO-3107, a DNA medicine candidate for recurrent ...